NCT04412629: Cabozantinib in High Grade Neuroendocrine Neoplasms

NCT04412629
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment with cabozantinib; Patients with unstable, symptomatic, uncontrolled brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04412629

Comments are closed.

Up ↑